Sochor and collaborators [18] found that high-risk patients (classified as TNBC, HER2, highly proliferative or with positive node involvement) expressed higher levels in plasma of miRNAs related to cancer (oncomiRs), including miR-2. The gene discussed is ERBB2; the disease is cancer.